Filing Flows

Filing Flows › Companies › Veracyte › Cash flow

Veracyte cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$37.9M in Q3 2026 · $162M over twelve months

Operating cash flow$40.3M
Capital spending−$2.3M
Free cash flow+$37.9M
Cash / net income1.3×

Analysis

In Q3 2026, Veracyte generated $40.3M of operating cash flow and spent $2.3M on capital projects, leaving free cash flow of $37.9M. That is $4.0M less than in Q3 2025 ($42.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was $174M; the largest uses were acquisitions ($153M), other investing ($121M), taxes on employees’ shares ($21.1M); besides operations, cash came from shares issued ($18.0M); the cash balance fell by $116M.

Operating cash flow was $40.3M against net income of $31.5M — 1.3× profit, cash ran ahead of reported earnings. The largest differences: stock-based pay +$14.0M, depreciation & amortization +$6.0M, receivables −$2.2M.

Free cash flow

Veracyte: free cash flow by quarterVeracyte: free cash flow by quarter$20.4MQ4 2024$3.5MQ1 2025$32.3MQ2 2025$42.0MQ3 2025$48.8MQ4 2025$32.3MQ1 2026$43.0MQ2 2026$37.9MQ3 2026
Operating cash flow less capital spending.
Veracyte: operating cash flow against capital spendingVeracyte: operating cash flow against capital spendingOperating cash flowCapital spending$24.5M$4.1MQ4 2024$5.4M$1.8MQ1 2025$33.6M$1.3MQ2 2025$44.8M$2.8MQ3 2025$52.6M$3.8MQ4 2025$35.2M$3.0MQ1 2026$45.8M$2.9MQ2 2026$40.3M$2.3MQ3 2026
Latest (Q3 2026): Operating cash flow $40.3M, Capital spending $2.3M.

Capital allocation, year by year

Veracyte: where the cash came from (up) and went (down), by fiscal yearVeracyte: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$31.6MFY2021: Shares issued $605MFY2021: Capital spending −$5.4MFY2021: Acquisitions −$574M$605MFY2021FY2022: Operating cash flow $7.5MFY2022: Net borrowing −$1.3MFY2022: Shares issued $7.9MFY2022: Capital spending −$8.5M$15.5MFY2022FY2023: Operating cash flow $44.2MFY2023: Shares issued $9.6MFY2023: Capital spending −$10.0M$53.8MFY2023FY2024: Operating cash flow $75.1MFY2024: Shares issued $20.0MFY2024: Capital spending −$11.3MFY2024: Acquisitions $5.0M$100MFY2024FY2025: Operating cash flow $136MFY2025: Shares issued $14.1MFY2025: Asset sales $2.9MFY2025: Capital spending −$9.7M$153MFY2025
Over these 5 years operating cash flow totalled $232M; the largest uses were acquisitions ($574M) and capital spending ($44.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$250M
Debtnone
Net cash$250M

Veracyte funds itself: free cash flow was $162M over the last twelve months, with $250M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Veracyte: sources (+) and uses (−) of cash, Q3 2026Veracyte: sources (+) and uses (−) of cash, Q3 2026Other investing−$137MCash drawn (+) / kept (−)$99.7MOperating cash flow$40.3MTaxes on employees’ shares−$3.8MShares issued$3.3MCapital spending−$2.3MExchange rates−$18K
Veracyte: sources (+) and uses (−) of cash, TTM to Q3 2026Veracyte: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$174MAcquisitions−$153MOther investing−$121MCash drawn (+) / kept (−)$116MTaxes on employees’ shares−$21.1MShares issued$18.0MCapital spending−$11.9MExchange rates−$90K

From profit to cash

Veracyte: net income to operating cash flow, Q3 2026Veracyte: net income to operating cash flow, Q3 2026Net income$31.5MDepreciation & amortization$6.0MStock-based pay$14.0MReceivables−$2.2MPayables$1.8MPrepaid and other assets−$1.7MOperating cash flow$40.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$40.3M−$2.3M$3.3M$99.7M$37.9M
Q2 2026$45.8M−$2.9M$8.4M−$36.4M$43.0M
Q1 2026$35.2M−$3.0M$2.7M$99.4M$32.3M
Q4 2025$52.6M−$3.8M$3.5M−$47.0M$48.8M
Q3 2025$44.8M−$2.8M$5.8M−$96.1M$42.0M
Q2 2025$33.6M−$1.3M$1.8M−$33.4M$32.3M
Q1 2025$5.4M−$1.8M$3.0M$52.9M$3.5M
Q4 2024$24.5M−$4.1M$3.3M$34.5M$20.4M

Veracyte: income statement and cash flow

Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%. The chart follows the revenue to costs, profit and cash.

Veracyte: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.